Investor Presentaiton

Investor presentation First three months of 2017 Slide 44 Novo Nordisk's modern insulins maintain market share in the US insulin market US fast-acting insulin Segment volume US premix insulin Segment volume US long-acting insulin Segment volume Levemir® share NovoLogⓇ share NovoLog® Mix 70/30 share TresibaⓇ share tMU tMU tMU CAGR volume¹: 3.1% 80 100% 80 MI penetration: 83.7% CAGR volume¹: (6.2%) MI penetration: 52.5% CAGR volume¹: 4.0% 100% 80 100% MI penetration: 79.3% 70 70 70 80% 80% 80% 60 60 60 50 40 - 60% 50 60% 50 - 60% 40 40 40% 40% 40% 30 20 10 0 Feb 2012 1 CAGR for 5-year period 30 30 20 20 20% 20% 20% 10 10 0% 0% 0 0% Feb 2017 0 Feb 2012 Feb 2017 Feb Feb 2012 2017 Note: US trend data reflect changes to IMS data collection coverage and methodology as of January 2012. Modern insulin (MI) penetration is of total segment, ie including human insulin Source: IMS Monthly MAT February, 2017 volume figures changing diabetes® novo nordisk

View entire presentation